Results 241 to 250 of about 25,109 (253)

Dual targeting of HER3 and MEK may overcome HER3-dependent chemoresistance of colon cancers

2014
The medical treatment of colorectal cancer (CRC) has evolved greatly in the last years, involving combined chemotherapy protocols and, more recently, new biologic agents. Nevertheless, prognosis remains adverse for patients with metastatic disease and a significant portion of early-stage patients develop recurrence after chemotherapy.
openaire   +2 more sources

A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer

Acta Pharmacologica Sinica
Huifang Zong, Xi Li, Lei Han, Lei Wang, Junjun Liu, Yali Yue, Jie Chen, Yong Ke, Hua Jiang, Yueqing Xie, Baohong Zhang, Jianwei Zhu   +11 more
semanticscholar   +1 more source

HER3, serious partner in crime

Pharmacology & Therapeutics, 2014
Arjan Kol, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer-Bosscha, Laetitia E. Lamberts, Frederike Bensch, Elisabeth G.E. de Vries, Carolina P. Schröder   +6 more
openaire   +1 more source

Moderne HER3-Antikörpertherapien durchbrechen Resistenzmechanismen

Im Fokus Onkologie, 2022
openaire   +1 more source

HER3

2008
openaire   +1 more source

SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs

Acta Pharmacologica Sinica
Wen-Jing Li, Cheng-Ying Xie, Xi Zhu, Jiao Tang, Lei Wang, Li-guang Lou   +5 more
semanticscholar   +1 more source

HER3

2011
openaire   +1 more source

HER3/ERbB-3

1997
openaire   +1 more source

382 Preclinical Pharmacokinetics of GE-huMab-HER3, a Novel Humanized, Glycoengineered Anti-HER3 Antibody Using PHER3/HER3 Ratio as Pharmacodynamics (PD) Marker

European Journal of Cancer, 2012
G. Meneses-Lorente, I. Kolm, M. Thomas, T. Friess, S. Bader, C. Meille, B. Bossenmaier   +6 more
openaire   +1 more source

HER3 (c-Erb-b3)

2008
openaire   +1 more source